Trial Profile
Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Tenecteplase (Primary) ; Aspirin; Clopidogrel
- Indications Stroke
- Focus Therapeutic Use
- Acronyms TEMPO-2
- 16 Mar 2024 Planned End Date changed from 1 Dec 2024 to 10 Apr 2024.
- 16 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 16 May 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.